Richard Morgan, Ph.D. Joins bluebird bio as Vice President of Immunotherapy
Published: Oct 01, 2013
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that Dr. Rick Morgan is joining the company as vice president of Immunotherapy.
Help employers find you! Check out all the jobs and post your resume.